Why This Matters
Glioblastoma is the most common primary brain cancer in adults and one of the most uniformly fatal. The standard treatment has not meaningfully changed in two decades: surgery, followed by radiation, followed by chemotherapy with temozolomide (TMZ). Median survival is approximately 15 months from diagnosis. That number has barely moved despite decades of research.
